Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ITI Immunity, Transplantation and INFECTION Context: • Infectious disease are directly responsible for a major fraction of global mortality. • Microbes now clearly implicated in the etiology of many other, chronic diseases, as well. • Major new diseases have recently emerged. Infectious diseases looming as biological weapons. New tools are in hand. New understanding of host-pathogen systems. Stanford and the U.S. have a responsibility to build partnerships with developing countries. 1 ITI 1. Infectious disease are directly responsible for a major fraction of global mortality. 2 1.1 Leading causes of death globally, 1999 ITI Rank % of total • 1 Ischaemic heart disease 12.7 • 2 Cerebrovascular disease 9.9 • 3 Acute lower respiratory infections 7.1 • 4 HIV/AIDS 4.8 • 5 Chronic obstructive pulmonary disease 4.8 • 6 Perinatal conditions 4.2 • 7 Diarrhoeal diseases 4.0 • 8 Tuberculosis 3.0 • 11 Malaria 1.9 N~55M Source: The World Health Report 2000, WHO 3 1.2 Leading causes of death in Africa, 1999 ITI Rank % of total • 1 HIV/AIDS 20.6 • 2 Acute lower respiratory infections 10.3 • 3 Malaria 9.1 • 4 Diarrhoeal diseases 7.3 • 5 Perinatal conditions 5.9 • 6 Measles 4.9 • 7 Tuberculosis 3.4 • 8 Cerebrovascular disease 3.2 • 9 Ischaemic heart disease 3.0 • 10 Maternal conditions 2.4 Source: The World Health Report 2000, WHO 4 ITI 1.3 Infectious diseases are responsible for a majority of deaths in children, worldwide. 5 ITI 2. Major new diseases have recently emerged. 6 ITI 1976 1976 1976 1982 1982 1983 1983 1989 1992 1993 1995 1996 1997 1999 2003 2.1 Many “New” Infectious Agents/Diseases Have Been Identified Since 1975. Cryptosporidium parvum (Cryptosporidiosis) Legionella (Legionnaire’s Disease) Ebola Virus (Ebola) E. coli O157 (lethal food poisoning) Borrelia burgdorferi (Lyme Disease) HIV (AIDS) Helicobacter pylori (peptic ulcers) Hepatitis C (nonA-nonB Hepatitis) Vibrio cholerae 0139 (new, virulent serotype of Cholera) Four Corners/Sin Nombre Virus (Hantavirus Pulmonary Syndrome) Human Herpesvirus 8 (Kaposi’s Sarcoma) Prions (variant Creutzfeld-Jacob Disease = “Mad Cow” in humans) H5N1 Influenza virus (Direct bird to human, super-virulent Flu) West Nile Virus (in N. America - Encephalitis) SARS coronavirus (SARS) 7 2.2 HIV is Reversing Hard-Won Improvements in Life Expectancy in many African Countries. ITI 65 60 Botswana Uganda South-Africa 55 Zambia 50 Zimbabwe 45 40 35 1950-55 1955-601960-651965-701970-751975-801980-851985-901990-951995-00 Source: United Nations Population Division, 1998 8 ITI 3. Microbes now clearly implicated in the etiology of many chronic diseases. 9 ITI 3.1 Microbes and Cancer. •Human papilloma virus and cervical carcinoma. •Hepatitis B and C viruses and hepatocellular carcinoma. •Helicobacter and gastric cancer. •Schistosoma and bladder cancer. 10 ITI 3.2 Microbes and Allergy. Hygiene hypothesis (“idle hands are the devil’s plaything”): elimination of certain infections leads to inappropriate immune response to environmental materials. 11 ITI 3.3 Microbes and Autoimmunity. Microbes may be triggers of an immune response to “self”. 12 ITI 4. New tools are in hand. 13 4.1 New tools (many developed here): ITI •‘omics of the pathogens, vectors and hosts. •Methods for engineering each. •HUGE increase in our understanding of the immune system and pathogen systems. •High throughput methods for analysis of host and pathogen. •Major developments in imaging. 14 ITI 5. We have a new understanding of hostpathogen systems. 15 5.1 Microbial ecology in and out of the host. ITI •We are hosts for a diverse community of microbes. •More microbial cells than human cells in humans. •More microbial genes than human genes in humans. •Much crucial metabolism occurs in the microbes. •Natural keep “unnatural” at bay. •Environmental changes create new opportunities for infection. 16 ITI 6. Questions to be addressed on the Infection side of ITI: •What factors lead to the emergence of new infectious diseases in humans? •How do microbial infections lead to chronic disease? •How does the interplay of complex microbial populations contribute to this? •What is the interplay of host and microbial genetics? •How can immunity be down-modulated to accept a transplanted organ but not infection? •How can vaccines and immune therapy be made more effective; e.g., for complex diseases? •How can immunity be stimulated in the very young or old? 17 ITI 7. Why Stanford? • Many world leaders in component areas. Many more studying diseases with infectious etiologies. A Vaccine Center has already been established. Stanford is a major power in genetics, ‘omics, imaging, immune monitoring, etc. 18 ITI And, finally, some examples of what’s happening now at Stanford. • Development of novel vaccines in and for developing countries (e.g., rotavirus); Harry Greenberg, Gastroenterology. • Helicobacter and its association with gastric (up) and esophageal (down) cancer. Julie Parsonnet, Infectious Diseases and Stanley Falkow, Microbiology and Immunology. • Cytomegalovirus association with cardiovascular disease; Ed Mocarski, Microbiology and Immunology, Hannah Valantine & John Cooke, Medicine and Dave Lewis, Pediatrics. • Development of model host-pathogen systems; Man Wah Tan, Genetics and Brendan Bohannan, Biological Sciences. • Infection signatures (including smallpox); David Relman, Infectious Diseases and Pat Brown, Biochemistry. • Molecular mimicry of immune modulators by pathogens (e.g., viral IL6). Chris Garcia, Microbiology and Immunology. 19 ITI 20 ITI New infections with HIV in 2003. Total: 4.2 - 5.8M 30-40k 180-280k 36-54k 43-67k Slide 2 150-270k 610-1100k 120-180k 3000-3400k 0.7-1k Source: WHO 21 100% 90% Risk of dying of AIDS ITI Lifetime risk of AIDS death for 15-year-old boys in selected countries Botswana 80% Zimbabwe 70% 60% 50% Côte d’Ivoire Cambodia Burkina 20% Faso 10% 0% Zimbabwe South Africa Zambia Kenya 40% 30% Botswana South Africa Zambia 0% risk halved over next 15 years current level of risk maintained Kenya Côte d’Ivoire Cambodia Burkina Faso 5% 10% 15% 20% 25% 30% 35% 40% Current adult HIV prevalence rate Source: Zaba B, 2000 (unpublished data) 22